Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 211
Filtrar
1.
Mol Syndromol ; 4(1-2): 87-93, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23653579

RESUMO

Patients with Fanconi anemia (FA) often have birth defects that suggest the diagnosis of VATER association. A review of 2,245 cases of FA reported in the literature from 1927 to 2012 identified 108 cases with at least 3 of the defining features of VATER association; only 29 had been so noted by the authors. The FA VATER signature was the significantly higher frequency of renal and limb (radial and/or thumb) anomalies (93% of cases had both) compared with less than 30% of VATER patients; the presence of one or both of these birth defects should lead to testing for FA. The relative frequencies of the genotypes of the patients with FA VATER were strikingly different from those expected from the general FA population; only 19% were FANCA, while 21% were FANCB, 14% FANCD1/BRCA2, and 12% FANCD2. Consistent with their genotypes, those with the FA VATER phenotype had a worse prognosis than FA patients with milder phenotypes, with shorter median survival and earlier onset of malignancies. The early identification of FA patients among infants with VATER association should lead to earlier more proactive management, such as cancer surveillance and genetic counseling.

2.
Bone Marrow Transplant ; 46(1): 98-104, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20383216

RESUMO

Dyskeratosis congenita (DC) is characterized by reticular skin pigmentation, oral leukoplakia and abnormal nails. Patients with DC have very short telomeres and approximately one-half have mutations in telomere biology genes. A majority of patients with DC develop BM failure (BMF). Hematopoietic cell transplantation (HCT) represents the only known cure for BMF in DC, but poses significant toxicities. We report six patients who underwent allogeneic HCT with a novel nonmyeloablative conditioning regimen specifically designed for DC patients. Graft sources included related PBSCs (1), unrelated BM (2) and unrelated double umbilical cord blood (3). Complete donor engraftment was achieved in five of six patients. One patient had initial autologous hematopoietic recovery, which was followed by a second transplant that resulted in 88% donor chimerism. With a median follow-up of 26.5 months, four patients are alive, three of whom were recipients of unrelated grafts. We conclude with this small study that encouraging short-term survival can be achieved with HCT in patients with DC using a preparative regimen designed to promote donor engraftment and minimize life-threatening disease-specific complications such as pulmonary fibrosis. Long-term follow-up will be crucial with respect to individualized patient care with each of the transplanted individuals.


Assuntos
Disceratose Congênita/terapia , Transplante de Células-Tronco Hematopoéticas , Condicionamento Pré-Transplante/métodos , Adolescente , Alemtuzumab , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Anticorpos Antineoplásicos/administração & dosagem , Anticorpos Antineoplásicos/efeitos adversos , Anticorpos Antineoplásicos/uso terapêutico , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Transplante de Medula Óssea/efeitos adversos , Pré-Escolar , Terapia Combinada/efeitos adversos , Transplante de Células-Tronco de Sangue do Cordão Umbilical/efeitos adversos , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Ciclofosfamida/uso terapêutico , Disceratose Congênita/fisiopatologia , Feminino , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Masculino , Transplante de Células-Tronco de Sangue Periférico/efeitos adversos , Fibrose Pulmonar/etiologia , Fibrose Pulmonar/prevenção & controle , Condicionamento Pré-Transplante/efeitos adversos , Vidarabina/administração & dosagem , Vidarabina/efeitos adversos , Vidarabina/análogos & derivados , Vidarabina/uso terapêutico , Irradiação Corporal Total/efeitos adversos , Adulto Jovem
3.
Br J Pharmacol ; 160(3): 549-60, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20590565

RESUMO

BACKGROUND AND PURPOSE: Inhibitors of fatty acid amide hydrolase (FAAH), the enzyme responsible for the metabolism of the endogenous cannabinoid (CB) receptor ligand anandamide (AEA), are effective in a number of animal models of pain. Here, we investigated a series of isoflavones with respect to their abilities to inhibit FAAH. EXPERIMENTAL APPROACH: In vitro assays of FAAH activity and affinity for CB receptors were used to characterize key compounds. In vivo assays used were biochemical responses to formalin in anaesthetized mice and the 'tetrad' test for central CB receptor activation. KEY RESULTS: Of the compounds tested, biochanin A was adjudged to be the most promising. Biochanin A inhibited the hydrolysis of 0.5 microM AEA by mouse, rat and human FAAH with IC(50) values of 1.8, 1.4 and 2.4 microM respectively. The compound did not interact to any major extent with CB(1) or CB(2) receptors, nor with FAAH-2. In anaesthetized mice, URB597 (30 microg i.pl.) and biochanin A (100 microg i.pl.) both inhibited the spinal phosphorylation of extracellular signal-regulated kinase produced by the intraplantar injection of formalin. The effects of both compounds were significantly reduced by the CB(1) receptor antagonist/inverse agonist AM251 (30 microg i.pl.). Biochanin A (15 mg.kg(-1) i.v.) did not increase brain AEA concentrations, but produced a modest potentiation of the effects of 10 mg.kg(-1) i.v. AEA in the tetrad test. CONCLUSIONS AND IMPLICATIONS: It is concluded that biochanin A, in addition to its other biochemical properties, inhibits FAAH both in vitro and peripherally in vivo.


Assuntos
Amidoidrolases/antagonistas & inibidores , Genisteína/farmacologia , Isoflavonas/farmacologia , Animais , Ácidos Araquidônicos/metabolismo , Comportamento Animal/efeitos dos fármacos , Benzamidas/antagonistas & inibidores , Benzamidas/farmacologia , Encéfalo/efeitos dos fármacos , Encéfalo/enzimologia , Encéfalo/metabolismo , Células COS , Antagonistas de Receptores de Canabinoides , Carbamatos/antagonistas & inibidores , Carbamatos/farmacologia , Linhagem Celular Transformada , Chlorocebus aethiops , Interações Medicamentosas , Endocanabinoides , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Formaldeído/antagonistas & inibidores , Genisteína/antagonistas & inibidores , Humanos , Fígado/enzimologia , Camundongos , Camundongos Endogâmicos ICR , Piperidinas/farmacologia , Alcamidas Poli-Insaturadas/metabolismo , Pirazóis/farmacologia , Ratos
4.
Oral Dis ; 14(5): 419-27, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18938267

RESUMO

Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome that is characterized by lacey reticular hyperpigmentation of the skin, dystrophic nails, mucous membrane leukoplakia and pancytopenia. Diagnosis may be delayed until clinical signs are apparent. Severe pancytopenia frequently causes early mortality of DC patients, who have an increased risk of developing oropharyngeal squamous cell carcinoma. Several case reports have described oral changes in DC, which include oral leukoplakia, increased dental caries, hypodontia, thin enamel structure, aggressive periodontitis, intraoral brown pigmentation, tooth loss, taurodontism and blunted roots. We determined the prevalence of these previously reported findings in a cohort of 17 patients with DC and 23 family members. The most common oral changes in DC patients were oral leukoplakia (65% of the entire DC population), decreased root/crown ratio (75% with sufficient tooth development) and mild taurodontism (57% with sufficient tooth development). From the clinical perspective, a diagnosis of DC or other inherited bone marrow failure syndrome should be considered in young persons with oral leukoplakia, particularly those with no history of smoking. Multiple permanent teeth with decreased root/crown ratios further suggest DC.


Assuntos
Disceratose Congênita/complicações , Leucoplasia Oral/complicações , Doenças da Boca/complicações , Anormalidades Dentárias/complicações , Adolescente , Adulto , Estudos de Casos e Controles , Estudos de Coortes , Estudos Transversais , Índice CPO , Cavidade Pulpar/anormalidades , Dentição Permanente , Família , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Odontometria , Valores de Referência , Coroa do Dente/anormalidades , Raiz Dentária/anormalidades
5.
Zentralbl Chir ; 130(3): 260-6, 2005 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-15965881

RESUMO

INTRODUCTION: Despite the increasing acceptance of the TEP-procedure by patients and general practitioners this method has to be further examined. In addition to the classic surgical criteria of examination, subjective aspects of patient comfort must be taken into consideration as they are getting more and more significant for the evaluation of different methods. METHODS: According to this targets patients were clinically examined and questioned about specific topics regarding their quality of life after TEP-surgery and evaluated prospectively. RESULTS: Between 1995 and 2000 endoscopic total extraperitoneal hernioplasty (TEP) was used for 200 inguinal hernia repairs in 195 patients. 195 patients could be interviewed about the operation's outcome and examined physically and sonographically after 3 months, 188 patients after 6 months and 184 patients after 12 months post-op. The recurrence rate was 1.7 %, the rate of major complications was < 1 %. Sensitivity disorders were found in 7.3 % of all cases at the final examination prior to discharging but none at the 3 months check-up. The median postoperative period until the resumption of sexual intimacy was approximately two weeks, but one male patient reported about long-lasting pain in copulation (0.51 %). DISCUSSION: With regard to the aspects mentioned above, the TEP-procedure provided excellent results in the examined patient cohort and therefore turned out to be at least comparable with competitive endoscopic methods. A remarkable new finding was that patients could go back to work on average 2 weeks earlier than regaining their everyday fitness.


Assuntos
Hérnia Inguinal/cirurgia , Laparoscopia/métodos , Politetrafluoretileno , Complicações Pós-Operatórias/cirurgia , Próteses e Implantes , Telas Cirúrgicas , Atividades Cotidianas/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde , Dor Pós-Operatória/etiologia , Satisfação do Paciente , Complicações Pós-Operatórias/etiologia , Recidiva , Reoperação , Avaliação da Capacidade de Trabalho
7.
Hum Mol Genet ; 10(4): 371-82, 2001 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-11157800

RESUMO

We have cloned, sequenced and annotated segments of DNA spanning the mouse, chicken and pufferfish alpha globin gene clusters and compared them with the corresponding region in man. This has defined a small segment ( approximately 135-155 kb) of synteny and conserved gene order, which may contain all of the elements required to fully regulate alpha globin gene expression from its natural chromosomal environment. Comparing human and mouse sequences using previously described methods failed to identify the known regulatory elements. However, refining these methods by ranking identity scores of non-coding sequences, we found conserved sequences including the previously characterized alpha globin major regulatory element. In chicken and pufferfish, regions that may correspond to this element were found by analysing the distribution of transcription factor binding sites. Regions identified in this way act as strong enhancer elements in expression assays. In addition to delimiting the alpha globin chromosomal domain, this study has enabled us to develop a more sensitive and accurate routine for identifying regulatory elements in the human genome.


Assuntos
Cromossomos/química , Cromossomos/genética , Globinas/genética , Família Multigênica/genética , Sequências Reguladoras de Ácido Nucleico , Animais , Sequência de Bases , Galinhas , Sequência Conservada/genética , Ilhas de CpG/genética , Evolução Molecular , Peixes , Globinas/química , Humanos , Camundongos , Dados de Sequência Molecular , Hibridização de Ácido Nucleico/métodos , Estrutura Terciária de Proteína/genética , Sequências Reguladoras de Ácido Nucleico/fisiologia
8.
J Pediatr Hematol Oncol ; 23(7): 464-8, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11878584

RESUMO

Griscelli syndrome (GS) is a rare inherited disease characterized by immunodeficiency and partial albinism. The microscopic findings of the skin and hair are highly suggestive of the disease. The GS locus colocalizes on chromosome 15q21 with the myosin-Va gene (MYO5a), and mutations have been identified in few patients. We describe a 2-month-old Hispanic girl with severe pancytopenia secondary to hemophagocytosis. Even though a mutation at the Griscelli locus had not been identified, her clinical features and outcome were typical of GS. The purpose of this article is to alert physicians to the association between GS and hemophagocytosis. We suggest that GS should be considered in infants with hemophagocytosis because the features of partial albinism can be subtle. The relevant literature is summarized.


Assuntos
Albinismo/complicações , Histiocitose de Células não Langerhans/complicações , Síndromes de Imunodeficiência/complicações , Pancitopenia/complicações , Albinismo/diagnóstico , Autofagia , Criança , Pré-Escolar , Diagnóstico Diferencial , Feminino , Histiocitose de Células não Langerhans/diagnóstico , Humanos , Síndromes de Imunodeficiência/diagnóstico , Lactente , Recém-Nascido , Masculino , Pancitopenia/diagnóstico , Recidiva , Síndrome
9.
J Pediatr ; 137(6): 882-6, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11113849

RESUMO

Early death in Schimke immuno-osseous dysplasia often results from renal failure and/or cell-mediated immunodeficiency. Kidney transplants have improved renal function, but effective therapy for the immunodeficiency has not yet been reported. We describe markedly improved marrow function 2 years after bone marrow transplantation in a boy with Schimke immunoosseous dysplasia.


Assuntos
Transplante de Medula Óssea , Osteocondrodisplasias/genética , Osteocondrodisplasias/terapia , Antígenos CD/sangue , Criança , Pré-Escolar , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Imunossupressores/uso terapêutico , Recém-Nascido , Transplante de Rim , Linfopenia/complicações , Linfopenia/diagnóstico , Masculino , Osteocondrodisplasias/complicações , Linhagem , Insuficiência Renal/complicações , Insuficiência Renal/cirurgia , Tacrolimo/uso terapêutico
10.
Cancer Genet Cytogenet ; 117(2): 125-31, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10704682

RESUMO

The adverse potential of the development of myelodysplastic syndrome (MDS) in Fanconi anemia (FA) was examined in a retrospective study of 41 FA patients who had bone marrow morphology and chromosomes reviewed by a single group. Thirty-three patients had adequate cytogenetic studies, and 16 (48%) had one or more abnormal studies: nine initially, and seven more on follow-up. Cytogenetic clonal variation was frequent, including disappearance of clones, clonal evolution, and appearance of new clones. The estimated five-year survival with a cytogenetic clone is 0.40, compared to 0.94 without a clone. Morphologic myelodysplasia (MDS), independent of a cytogenetic clone, was found in 13/41 patients (32%). The estimated five-year survival with MDS is 0.09, versus 0.92 without MDS. Leukemia developed in three patients whose initial cytogenetic clones prior to leukemia were t(1;18), t(5;22) and monosomy 7; the one with t(1;18) also had MDS. Our results focus on marrow morphology, and suggest that morphologic MDS may be more important than classical cytogenetics in prediction of an adverse outcome.


Assuntos
Anemia de Fanconi/complicações , Anemia de Fanconi/mortalidade , Síndromes Mielodisplásicas/etiologia , Adolescente , Adulto , Medula Óssea/patologia , Criança , Pré-Escolar , Células Clonais , Anemia de Fanconi/genética , Anemia de Fanconi/patologia , Feminino , Humanos , Cariotipagem , Masculino , Síndromes Mielodisplásicas/genética , Síndromes Mielodisplásicas/patologia , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida
12.
Br J Haematol ; 107(1): 49-54, 1999 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-10520024

RESUMO

Pregnancy in bone marrow failure syndromes has risk to mother and fetus. There are fewer than 30 reports of cases with Diamond-Blackfan anaemia (DBA), and none with Shwachman-Diamond syndrome (SD). We report two DBA and one SD cases. One DBA mother received transfusions intra-partum, and the other only post-partum. Both required caesarean sections (C-sections) for failure of labour to progress and severe pre-eclampsia respectively. Both subsequently resumed pre-pregnancy steroid-induced control of anaemia. approximately 40% of DBA pregnancies required maternal transfusions; 25% delivered by C-section. The SD patient also had Ehlers-Danlos (ED) syndrome and urticaria pigmentosa (UP). Her blood counts were adequate until week 38, when the platelet count dropped and a C-section was performed. Pregnancy management in marrow failure disorders requires obstetricians with expertise in high-risk pregnancies, and haematologists with experience with marrow failure syndromes.


Assuntos
Transfusão de Sangue/métodos , Doenças da Medula Óssea/terapia , Insuficiência Pancreática Exócrina/terapia , Anemia de Fanconi/terapia , Neutropenia/terapia , Complicações Hematológicas na Gravidez/terapia , Adulto , Cesárea , Feminino , Humanos , Gravidez , Fatores de Risco , Síndrome
13.
Clin Lab Med ; 19(1): 113-33, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10403077

RESUMO

Laboratory diagnosis of inherited bone marrow failure syndromes includes general evaluations, such as blood counts, examination of the peripheral blood smear for morphology, and bone marrow aspirates and biopsies, which may help the clinician classify the patient, particularly if there are no characteristic physical anomalies. Specific diagnoses require unique tests that are only available for a few of the diagnoses. The most useful is chromosome breakage in the diagnosis of FA, with gene mutation analysis or mapping about to become the gold standard when all of the FA genes have been cloned. The diagnosis of DC remains clinical at this time, although linkage to Xq28 and skewed maternal X inactivation may be helpful in some families. Laboratory proof of SD may be provided by decreased serum trypsinogen or other evidence of exocrine pancreatic insufficiency. CHH is substantiated when absent central pigment in hair is found and when it is mapped to 9p21-p13. The only mitochondrial syndrome, PS, is proved with demonstration of deleted mitochondrial DNA. RD is diagnosed from blood and marrow studies that demonstrate lack of lymphoid as well as myeloid activity. Amega requires absent or abnormal marrow megakaryocytes; if radii are also absent, the diagnosis is TAR. DBA usually has elevated red-cell ADA, and the DBA locus may map to 19q13. KS is diagnosed in patients who have congenital nonimmune severe neutropenia. Clinical suspicion of particular diagnoses can often be substantiated by laboratory tests of varying specificity.


Assuntos
Doenças da Medula Óssea , Doenças da Medula Óssea/diagnóstico , Doenças da Medula Óssea/genética , Criança , Pré-Escolar , Testes Hematológicos , Humanos , Lactente , Recém-Nascido , Síndrome
14.
Blood ; 94(1): 359-61, 1999 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-10381533

RESUMO

Human embryonic zeta and epsilon globin chains are synthesized in yolk sac-derived primitive erythroid cells, and decrease rapidly during definitive erythropoiesis. Examination of zeta and epsilon globin expression at the cellular level using dual-color immunofluorescence staining with specific monoclonal antibodies showed that embryonic globin proteins are present in definitive erythroid cells. More than half of fetal erythrocytes were positive for zeta and approximately 5% for epsilon globin. Approximately one third of newborn red blood cells were zeta-positive and less than 1% epsilon-positive. Adult erythrocytes did not have embryonic globins. Erythroblasts that developed in liquid cultures also contained embryonic globin in amounts which declined with ontogenic age, and the proportion of positive cells in vitro was less than in the comparable erythrocytes that developed in vivo. Thus, embryonic globin chains are synthesized in definitive erythroid cells and decrease with ontogeny. Modulation of embryonic globin gene expression is not solely due to a switch from primitive to definitive erythropoiesis.


Assuntos
Eritroblastos/metabolismo , Eritrócitos/metabolismo , Hemoglobina Fetal/biossíntese , Feto/metabolismo , Adulto , Diferenciação Celular , Eritroblastos/citologia , Feto/citologia , Humanos , Recém-Nascido
17.
Curr Opin Hematol ; 5(3): 226-34, 1998 May.
Artigo em Inglês | MEDLINE | ID: mdl-9664165

RESUMO

The use of hematopoietic growth factors, although well established for the management of chemotherapy-induced neutropenia, remains controversial for the treatment of aplastic anemia and inherited bone marrow failure syndromes. The most commonly used factors are granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, and erythropoietin. Newer growth factors such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising results in the laboratory, and some have been used in clinical trials. This article reviews the clinical use of old and new hematopoietic growth factors in acquired and inherited bone marrow failure, and discusses emerging concerns about long term toxicity of these factors.


Assuntos
Anemia Aplástica/tratamento farmacológico , Fatores de Crescimento de Células Hematopoéticas/uso terapêutico , Doenças da Medula Óssea/tratamento farmacológico , Ensaios Clínicos como Assunto , Eritropoetina/uso terapêutico , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Humanos , Fator de Células-Tronco/uso terapêutico
20.
Am J Med Sci ; 314(2): 113-7, 1997 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9258213

RESUMO

We report the case of a 34-year-old woman with recurrent pure red cell aplasia and evidence of hepatitis B and C infection. Review of the English literature identified 19 prior cases in which pure red cell aplasia was associated with hepatitis. This case is the first in which serologic evidence of hepatitis C infection was documented. This patient also had porphyria cutanea tarda and marked hepatic siderosis but no active hepatitis or cirrhosis. Treatment with cyclophosphamide and prednisone produced complete remission of the pure red cell aplasia. Erythroid colony formation (colony-forming unit-erythroid and erythroid burst-forming unit) was reduced in cultures of bone marrow obtained during relapse but was normal in remission marrow. However, addition of the patient serum, whether collected during relapse or remission, inhibited erythroid colony formation by her bone marrow. These observations, and the known extrahepatic immunologic manifestations of hepatitis C infection, suggest that the pure red cell aplasia occurred because of autoimmune mechanism provoked by the infection.


Assuntos
Medula Óssea/fisiopatologia , Eritropoese , Hepatite C/complicações , Aplasia Pura de Série Vermelha/fisiopatologia , Adulto , Células Precursoras Eritroides , Feminino , Hepatite C/fisiopatologia , Humanos , Recidiva , Aplasia Pura de Série Vermelha/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...